HMGB1–Platelet Interactions: Mechanisms and Targeted Therapy Strategies

Abstract

Platelets serve not only as crucial hemostatic components but also as pivotal regulators of inflammatory responses, capable of interacting with diverse cell types and secreting abundant extracellular factors. Accumulating evidence demonstrates that high mobility group box 1 (HMGB1), a DNA-binding protein and critical inflammatory mediator, plays multifaceted roles in disease progression, with platelets being one cellular source of circulating HMGB1. Under pathological conditions, platelets release HMGB1 into the extracellular matrix, establishing bidirectional communication between platelets and other immune cells. Moreover, HMGB1 reciprocally activates platelets through Toll-like receptors (TLRs) and receptor for advanced glycation end-products (RAGE), facilitating platelet activation and subsequent release of regulatory factors that drive inflammation-associated pathological thrombosis. In this review, we systematically characterize the HMGB1–platelet axis and elucidate its context-dependent roles in specific disease states. The mechanistic interplay between HMGB1 signaling and platelet pathophysiology is discussed, particularly its implications for disease progression. Furthermore, we critically evaluate therapeutic strategies targeting HMGB1 developed over the past decade, while proposing future directions for dual-target interventions that simultaneously modulate HMGB1 and platelet activity to combat inflammation-driven thrombotic disorders.

Keywords

HMGB1 - platelet activation - proinflammatory - therapy

^* These authors have contributed equally as co-first authors.

Publikationsverlauf

Eingereicht: 05. April 2025

Angenommen: 23. Mai 2025

Artikel online veröffentlicht:
13. Juni 2025

• References

• 1 Andrews RK, Berndt MC. Platelet physiology and thrombosis. Thromb Res 2004; 114 (5–6): 447-453
• 2 Kulkarni S, Dopheide SM, Yap CL. et al. A revised model of platelet aggregation. J Clin Invest 2000; 105 (06) 783-791
• 3 Mandel J, Casari M, Stepanyan M, Martyanov A, Deppermann C. Beyond hemostasis: platelet innate immune interactions and thromboinflammation. Int J Mol Sci 2022; 23 (07) 3868
• 4 Storey R, Thomas M. The role of platelets in inflammation. Thromb Haemost 2017; 114 (09) 449-458
• 5 Hoffman R, Haim N, Brenner B. Cancer and thrombosis revisited. Blood Rev 2001; 15 (02) 61-67
• 6 Read CM, Cary PD, Crane-Robinson C, Driscoll PC, Norman DG. Solution structure of a DNA-binding domain from HMG1. Nucleic Acids Res 1993; 21 (15) 3427-3436
• 7 Stott K, Watson M, Howe FS, Grossmann JG, Thomas JO. Tail-mediated collapse of HMGB1 is dynamic and occurs via differential binding of the acidic tail to the A and B domains. J Mol Biol 2010; 403 (05) 706-722
• 8 Shi Q, Wang Y, Dong W, Song E, Song Y. Polychlorinated biphenyl quinone-induced signaling transition from autophagy to apoptosis is regulated by HMGB1 and p53 in human hepatoma HepG2 cells. Toxicol Lett 2019; 306: 25-34
• 9 Kang R, Livesey KM, Zeh IIIHJ, Loze MT, Tang D. HMGB1: a novel Beclin 1-binding protein active in autophagy. Autophagy 2014; 6 (08) 1209-1211
• 10 Bell CW, Jiang W, Reich CF, Pisetsky DS. The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol 2006; 291 (06) C1318-C1325
• 11 Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418 (6894) 191-195
• 12 Chen G, Ward MF, Sama AE, Wang H. Extracellular HMGB1 as a proinflammatory cytokine. J Interferon Cytokine Res 2004; 24 (06) 329-333
• 13 Dumitriu IE, Baruah P, Manfredi AA, Bianchi ME, Rovere-Querini P. HMGB1: guiding immunity from within. Trends Immunol 2005; 26 (07) 381-387
• 14 Fiuza C, Bustin M, Talwar S. et al. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 2003; 101 (07) 2652-2660
• 15 Lee S-A, Kwak MS, Kim S, Shin J-S. The role of high mobility group box 1 in innate immunity. Yonsei Med J 2014; 55 (05) 1165-1176
• 16 Venereau E, Schiraldi M, Uguccioni M, Bianchi ME. HMGB1 and leukocyte migration during trauma and sterile inflammation. Mol Immunol 2013; 55 (01) 76-82
• 17 Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 2010; 28 (01) 367-388
• 18 Maugeri N, Franchini S, Campana L. et al. Circulating platelets as a source of the damage-associated molecular pattern HMGB1 in patients with systemic sclerosis. Autoimmunity 2012; 45 (08) 584-587
• 19 Feldman C, Anderson R. Platelets and their role in the pathogenesis of cardiovascular events in patients with community-acquired pneumonia. Front Immunol 2020; 11: 577303
• 20 Lim KH, Staudt LM. Toll-like receptor signaling. Cold Spring Harb Perspect Biol 2013; 5 (01) a011247
• 21 O'Neill LAJ, Golenbock D, Bowie AG. The history of Toll-like receptors—redefining innate immunity. Nat Rev Immunol 2013; 13 (06) 453-460
• 22 Bolourani S, Brenner M, Wang P. The interplay of DAMPs, TLR4, and proinflammatory cytokines in pulmonary fibrosis. J Mol Med 2021; 99 (10) 1373-1384
• 23 Aslam R, Speck ER, Kim M. et al. Platelet Toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-α production in vivo. Blood 2006; 107 (02) 637-641
• 24 Zhang Y, Liang X, Bao X, Xiao W, Chen G. Toll-like receptor 4 (TLR4) inhibitors: current research and prospective. Eur J Med Chem 2022; 235: 114291
• 25 Rouhiainen A, Imai S, Rauvala H, Parkkinen J. Occurrence of amphoterin (HMG1) as an endogenous protein of human platelets that is exported to the cell surface upon platelet activation. Thromb Haemost 2000; 84 (06) 1087-1094
• 26 Vogel S, Bodenstein R, Chen Q. et al. Platelet-derived HMGB1 is a critical mediator of thrombosis. J Clin Invest 2015; 125 (12) 4638-4654
• 27 Li Z, Xi X, Gu M. et al. A stimulatory role for cGMP-dependent protein kinase in platelet activation. Cell 2003; 112 (01) 77-86
• 28 Kierdorf K, Fritz G. RAGE regulation and signaling in inflammation and beyond. J Leukoc Biol 2013; 94 (01) 55-68
• 29 Lappas M, Permezel M, Rice GE. Advanced glycation endproducts mediate pro-inflammatory actions in human gestational tissues via nuclear factor-κB and extracellular signal-regulated kinase 1/2. J Endocrinol 2007; 193 (02) 269-277
• 30 Piarulli F, Lapolla A, Ragazzi E. et al. Role of endogenous secretory RAGE (esRAGE) in defending against plaque formation induced by oxidative stress in type 2 diabetic patients. Atherosclerosis 2013; 226 (01) 252-257
• 31 Basta G. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 2004; 63 (04) 582-592
• 32 Gawlowski T, Stratmann B, Ruetter R. et al. Advanced glycation end products strongly activate platelets. Eur J Nutr 2009; 48 (08) 475-481
• 33 Recabarren-Leiva D, Burgos CF, Hernandez B. et al. Effects of the age/rage axis in the platelet activation. Int J Biol Macromol 2021; 166: 1149-1161
• 34 Ahrens I, Chen YC, Topcic D. et al. HMGB1 binds to activated platelets via the receptor for advanced glycation end products and is present in platelet rich human coronary artery thrombi. Thromb Haemost 2015; 114 (05) 994-1003
• 35 Sakaguchi M, Murata HYamamoto K. et al. TIRAP, an adaptor protein for TLR2/4, transduces a signal from RAGE phosphorylated upon ligand binding. PLoS One 2011; 6 (08) e23132
• 36 van Beijnum JR, Nowak-Sliwinska P, van den Boezem E, Hautvast P, Buurman WA, Griffioen AW. Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1. Oncogene 2012; 32 (03) 363-374
• 37 Kojok K, El-Kadiry AE-H, Merhi Y. Role of NF-κB in platelet function. Int J Mol Sci 2019; 20 (17) 4185
• 38 Fuentes E, Rojas A, Palomo I. Role of multiligand/RAGE axis in platelet activation. Thromb Res 2014; 133 (03) 308-314
• 39 Paul M, Kemparaju K, Girish KS. Inhibition of constitutive NF-κB activity induces platelet apoptosis via ER stress. Biochem Biophys Res Commun 2017; 493 (04) 1471-1477
• 40 Cohn JN. Cardiovascular disease progression: a target for therapy?. Am J Med 2018; 131 (10) 1170-1173
• 41 Khodadi E. Platelet function in cardiovascular disease: activation of molecules and activation by molecules. Cardiovasc Toxicol 2019; 20 (01) 1-10
• 42 Thomas MR, Storey RF. The role of platelets in inflammation. Thromb Haemost 2015; 114 (03) 449-458
• 43 Huo Y, Schober A, Forlow SB. et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2002; 9 (01) 61-67
• 44 Langer H, Gawaz M. Platelet-vessel wall interactions in atherosclerotic disease. Thromb Haemost 2017; 99 (03) 480-486
• 45 Kalinina N, Agrotis A, Antropova Y. et al. Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2004; 24 (12) 2320-2325
• 46 de Souza AWS, Westra J, Limburg PC, Bijl M, Kallenberg CGM. HMGB1 in vascular diseases: its role in vascular inflammation and atherosclerosis. Autoimmun Rev 2012; 11 (12) 909-917
• 47 Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol 2015; 12 (08) 464-474
• 48 Mackman N. New insights into the mechanisms of venous thrombosis. J Clin Invest 2012; 122 (07) 2331-2336
• 49 Stark K, Philippi V, Stockhausen S. et al. Disulfide HMGB1 derived from platelets coordinates venous thrombosis in mice. Blood 2016; 128 (20) 2435-2449
• 50 Vogel S, Rath D, Borst O. et al. Platelet-derived high-mobility group box 1 promotes recruitment and suppresses apoptosis of monocytes. Biochem Biophys Res Commun 2016; 478 (01) 143-148
• 51 Brill A, Fuchs TA, Savchenko AS. et al. Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost 2012; 10 (01) 136-144
• 52 Martinod K, Witsch T, Farley K, Gallant M, Remold-O'Donnell E, Wagner DD. Neutrophil elastase-deficient mice form neutrophil extracellular traps in an experimental model of deep vein thrombosis. J Thromb Haemost 2016; 14 (03) 551-558
• 53 Martinod K, Wagner DD. Thrombosis: tangled up in NETs. Blood 2014; 123 (18) 2768-2776
• 54 Carestia A, Kaufman T, Schattner M. Platelets: new bricks in the building of neutrophil extracellular traps. Front Immunol 2016; 7: 271
• 55 Dyer MR, Chen Q, Haldeman S. et al. Deep vein thrombosis in mice is regulated by platelet HMGB1 through release of neutrophil-extracellular traps and DNA. Sci Rep 2018; 8 (01) 2068
• 56 Denorme F, Portier I, Rustad JL. et al. Neutrophil extracellular traps regulate ischemic stroke brain injury. J Clin Invest 2022; 132 (10) e154225
• 57 Singer M, Deutschman CS, Seymour CW. et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315 (08) 801-810
• 58 Semeraro N, Ammollo CT, Semeraro F, Colucci M. Sepsis, thrombosis and organ dysfunction. Thromb Res 2012; 129 (03) 290-295
• 59 Kaplan MJ, Radic M. Neutrophil extracellular traps: double-edged swords of innate immunity. J Immunol 2012; 189 (06) 2689-2695
• 60 Azevedo LCP, Janiszewski M, Pontieri V. et al. Platelet-derived exosomes from septic shock patients induce myocardial dysfunction. Crit Care (Fullerton) 2007; 11 (06) R120
• 61 Xu J, Feng Y, Jeyaram A, Jay SM, Zou L, Chao W. Circulating plasma extracellular vesicles from septic mice induce inflammation via microRNA- and TLR7-dependent mechanisms. J Immunol 2018; 201 (11) 3392-3400
• 62 Jiao Y, Li W, Wang W. et al. Platelet-derived exosomes promote neutrophil extracellular trap formation during septic shock. Crit Care (Fullerton) 2020; 24 (01) 380
• 63 Papayannopoulos V, Metzler KD, Hakkim A, Zychlinsky A. Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps. J Cell Biol 2010; 191 (03) 677-691
• 64 Maugeri N, De Lorenzo R, Clementi N. et al. Unconventional CD147-dependent platelet activation elicited by SARS-CoV-2 in COVID-19. J Thromb Haemost 2022; 20 (02) 434-448
• 65 Chen H, Ning Z, Qiu Y. et al. Elevated levels of von Willebrand factor and high mobility group box 1 (HMGB1) are associated with disease severity and clinical outcome of scrub typhus. Int J Infect Dis 2017; 61: 114-120
• 66 Arnout J, Vermylen J. Current status and implications of autoimmune antiphospholipid antibodies in relation to thrombotic disease. J Thromb Haemost 2003; 1 (05) 931-942
• 67 Lood C, Eriksson S, Gullstrand B. et al. Increased C1q, C4 and C3 deposition on platelets in patients with systemic lupus erythematosus—a possible link to venous thrombosis?. Lupus 2012; 21 (13) 1423-1432
• 68 Baroni Pietto MC, Glembotsky AC, Lev PR. et al. Toll-like receptor expression and functional behavior in platelets from patients with systemic lupus erythematosus. Immunobiology 2024; 229 (01) 152782
• 69 Postlethwaite AE, Chiang TM. Platelet contributions to the pathogenesis of systemic sclerosis. Curr Opin Rheumatol 2007; 19 (06) 574-579
• 70 Dees C, Akhmetshina A, Zerr P. et al. Platelet-derived serotonin links vascular disease and tissue fibrosis. J Exp Med 2011; 208 (05) 961-972
• 71 Yoshizaki A, Komura K, Iwata Y. et al. Clinical significance of serum HMGB-1 and sRAGE levels in systemic sclerosis: association with disease severity. J Clin Immunol 2008; 29 (02) 180-189
• 72 Manganelli V, Truglia S, Capozzi A. et al. Alarmin HMGB1 and soluble RAGE as new tools to evaluate the risk stratification in patients with the antiphospholipid syndrome. Front Immunol 2019; 10: 460
• 73 Kanne AM, Jülich M, Mahmutovic A. et al. Association of high mobility group box chromosomal protein 1 and receptor for advanced glycation end products serum concentrations with extraglandular involvement and disease activity in Sjögren's syndrome. Arthritis Care Res 2018; 70 (06) 944-948
• 74 Shafik NM, El-Esawy RO, Mohamed DA, Deghidy EA, El-Deeb OS. Regenerative effects of glycyrrhizin and/or platelet rich plasma on type-II collagen induced arthritis: targeting autophay machinery markers, inflammation and oxidative stress. Arch Biochem Biophys 2019; 675: 108095
• 75 Habets KLL, Huizinga TWJ, Toes REM. Platelets and autoimmunity. Eur J Clin Invest 2013; 43 (07) 746-757
• 76 Comings DE. A general theory of carcinogenesis. Proc Natl Acad Sci U S A 1973; 70 (12) 3324-3328
• 77 Brantley-Sieders DM, Fang WB, Hicks DJ, Zhuang G, Shyr Y, Chen J. Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression. FASEB J 2005; 19 (13) 1884-1886
• 78 Jube S, Rivera ZS, Bianchi ME. et al. Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res 2012; 72 (13) 3290-3301
• 79 Kang R, Hou W, Zhang Q. et al. RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer. Cell Death Dis 2014; 5 (10) e1480
• 80 Holmes CE, Levis JE, Ornstein DL. Activated platelets enhance ovarian cancer cell invasion in a cellular model of metastasis. Clin Exp Metastasis 2009; 26 (07) 653-661
• 81 Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer 2011; 11 (02) 123-134
• 82 Malte AL, Højbjerg JA, Larsen JB. Platelet parameters as biomarkers for thrombosis risk in cancer: a systematic review and meta-analysis. Semin Thromb Hemost 2023; 50 (03) 360-383
• 83 Sierko E, Wojtukiewicz MZ. Platelets and angiogenesis in malignancy. Semin Thromb Hemost 2004; 30 (01) 95-108
• 84 Kuznetsov HS, Marsh T, Markens BA. et al. Identification of luminal breast cancers that establish a tumor-supportive macroenvironment defined by proangiogenic platelets and bone marrow–derived cells. Cancer Discov 2012; 2 (12) 1150-1165
• 85 Janowska-Wieczorek A, Wysoczynski M, Kijowski J. et al. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer 2004; 113 (05) 752-760
• 86 Nierodzik ML, Karpatkin S. Thrombin induces tumor growth, metastasis, and angiogenesis: evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell 2006; 10 (05) 355-362
• 87 Fuentes E, Palomo I, Rojas A. Cross-talk between platelet and tumor microenvironment: role of multiligand/RAGE axis in platelet activation. Blood Rev 2016; 30 (03) 213-221
• 88 Yu L-X, Yan L, Yang W. et al. Platelets promote tumour metastasis via interaction between TLR4 and tumour cell-released high-mobility group box1 protein. Nat Commun 2014; 5: 5256
• 89 Yamanaka Y, Sawai Y, Nomura S. Platelet-derived microparticles are an important biomarker in patients with cancer-associated thrombosis. Int J Gen Med 2019; 12: 491-497
• 90 Nomura S, Fujita S, Ozasa R. et al. The correlation between platelet activation markers and HMGB1 in patients with disseminated intravascular coagulation and hematologic malignancy. Platelets 2011; 22 (05) 396-397
• 91 Pistoia V, Pezzolo A. Involvement of HMGB1 in resistance to tumor vessel-targeted, monoclonal antibody-based immunotherapy. J Immunol Res 2016; 2016: 1-7
• 92 Mega JL, Simon T. Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments. Lancet 2015; 386 (9990) 281-291
• 93 Guthikonda S, Lev EI, Kleiman NS. Resistance to antiplatelet therapy. Curr Cardiol Rep 2005; 7 (04) 242-248
• 94 Ekinci D, Sentürk M, Küfrevioğlu Ö. Salicylic acid derivatives: synthesis, features and usage as therapeutic tools. Expert Opin Ther Pat 2011; 21 (12) 1831-1841
• 95 Vlot AC, Dempsey DMA, Klessig DF. Salicylic acid, a multifaceted hormone to combat disease. Annu Rev Phytopathol 2009; 47 (01) 177-206
• 96 Choi HW, Tian M, Song F. et al. Aspirin's active metabolite salicylic acid targets high mobility group box 1 to modulate inflammatory responses. Mol Med 2015; 21 (01) 526-535
• 97 Yang H, Pellegrini L, Napolitano A. et al. Aspirin delays mesothelioma growth by inhibiting HMGB1-mediated tumor progression. Cell Death Dis 2015; 6 (06) e1786
• 98 Qin S, Wang H, Yuan R. et al. Role of HMGB1 in apoptosis-mediated sepsis lethality. J Exp Med 2006; 203 (07) 1637-1642
• 99 Levy RM, Mollen KP, Prince JM. et al. Systemic inflammation and remote organ injury following trauma require HMGB1. Am J Physiol Regul Integr Comp Physiol 2007; 293 (04) R1538-R1544
• 100 Nishibori M, Mori S, Takahashi HK. Anti-HMGB1 monoclonal antibody therapy for a wide range of CNS and PNS diseases. J Pharmacol Sci 2019; 140 (01) 94-101
• 101 Yang H, Ochani M, Li J. et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A 2004; 101 (01) 296-301
• 102 Yuan H, Jin X, Sun J. et al. Protective effect of HMGB1 a box on organ injury of acute pancreatitis in mice. Pancreas 2009; 38 (02) 143-148
• 103 Ulloa L, Ochani M, Yang H. et al. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci U S A 2002; 99 (19) 12351-12356
• 104 Pan P, Cardinal J, Dhupar R. et al. Low-dose cisplatin administration in murine cecal ligation and puncture prevents the systemic release of HMGB1 and attenuates lethality. J Leukoc Biol 2009; 86 (03) 625-632
• 105 Zetterström CK, Jiang W, Wähämaa H. et al. Pivotal advance: inhibition of HMGB1 nuclear translocation as a mechanism for the anti-rheumatic effects of gold sodium thiomalate. J Leukoc Biol 2008; 83 (01) 31-38
• 106 Hofmann MA, Drury S, Hudson BI. et al. RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun 2002; 3 (03) 123-135
• 107 Chen R-C, Yi P-P, Zhou R-R. et al. The role of HMGB1-RAGE axis in migration and invasion of hepatocellular carcinoma cell lines. Mol Cell Biochem 2014; 390 (1–2): 271-280
• 108 Lutterloh EC, Opal SM, Pittman DD. et al. Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection. Crit Care (Fullerton) 2007; 11 (06) R122
• 109 Mollica L, De Marchis F, Spitaleri A. et al. Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chem Biol 2007; 14 (04) 431-441
• 110 Abeyama K, Stern DM, Ito Y. et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest 2005; 115 (05) 1267-1274
• 111 Chorny A, Delgado M. Neuropeptides rescue mice from lethal sepsis by down-regulating secretion of the late-acting inflammatory mediator high mobility group box 1. Am J Pathol 2008; 172 (05) 1297-1302
• 112 Chorny A, Anderson P, Gonzalez-Rey E, Delgado M. Ghrelin protects against experimental sepsis by inhibiting high-mobility group box 1 release and by killing bacteria. J Immunol 2008; 180 (12) 8369-8377
• 113 Hagiwara S, Iwasaka H, Hasegawa A, Asai N, Noguchi T. High-dose intravenous immunoglobulin G improves systemic inflammation in a rat model of CLP-induced sepsis. Intensive Care Med 2008; 34 (10) 1812-1819
• 114 Klint Ea, Grundtman C, Engström M. et al. Intraarticular glucocorticoid treatment reduces inflammation in synovial cell infiltrations more efficiently than in synovial blood vessels. Arthritis Rheum 2005; 52 (12) 3880-3889
• 115 Dong H, Zhang L, Liu S. Targeting HMGB1: an available therapeutic strategy for breast cancer therapy. Int J Biol Sci 2022; 18 (08) 3421-3434
• 116 Tanuma S-i, Oyama T, Okazawa M. et al. A dual anti-inflammatory and anti-proliferative 3-styrylchromone derivative synergistically enhances the anti-cancer effects of DNA-damaging agents on colon cancer cells by targeting HMGB1-RAGE-ERK1/2 signaling. Int J Mol Sci 2022; 23 (07) 3426
• 117 Bedoui Y, Guillot X, Sélambarom J. et al. Methotrexate an old drug with new tricks. Int J Mol Sci 2019; 20 (20) 5023
• 118 Xie W, Zhou P, Sun Y. et al. Protective effects and target network analysis of ginsenoside Rg1 in cerebral ischemia and reperfusion injury: a comprehensive overview of experimental studies. Cells 2018; 7 (12) 270
• 119 Zhang Z, Zheng Y, Chen N. et al. San Huang Xiao Yan recipe modulates the HMGB1-mediated abnormal inflammatory microenvironment and ameliorates diabetic foot by activating the AMPK/Nrf2 signalling pathway. Phytomedicine 2023; 118: 154931
• 120 Zhang Y, Zhang J-X, Xiao L-X. et al. The synergistic effect of Huangqi Gegen decoction on thrombosis relates to the astragalus polysaccharide-improved oral delivery of puerarin. J Ethnopharmacol 2024; 335 (01) 118622
• 121 Xu D, Young J, Song D, Esko JD. Heparan sulfate is essential for high mobility group protein 1 (HMGB1) signaling by the receptor for advanced glycation end products (RAGE). J Biol Chem 2011; 286 (48) 41736-41744
• 122 Ebeyer-Masotta M, Eichhorn T, Weiss R. et al. Heparin-functionalized adsorbents eliminate central effectors of immunothrombosis, including platelet factor 4, high-mobility group box 1 protein and histones. Int J Mol Sci 2022; 23 (03) 1823
• 123 Sloos PH, Maas MAW, Meijers JCM. et al. Anti-high-mobility group box-1 treatment strategies improve trauma-induced coagulopathy in a mouse model of trauma and shock. Br J Anaesth 2023; 130 (06) 687-697
• 124 Park BS, Son DJ, Choi WS. et al. Antiplatelet activities of newly synthesized derivatives of piperlongumine. Phytother Res 2008; 22 (09) 1195-1199
• 125 Ku S-K, Kim JA, Bae J-S. Vascular barrier protective effects of piperlonguminine in vitro and in vivo. Inflamm Res 2014; 63 (05) 369-379
• 126 Francischetti IM, Monteiro RQ, Guimarães JA. Identification of glycyrrhizin as a thrombin inhibitor. Biochem Biophys Res Commun 1997; 235 (01) 259-263
• 127 Yang H, Antoine DJ, Andersson U, Tracey KJ. The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, and chemotaxis. J Leukoc Biol 2013; 93 (06) 865-873
• 128 Hudson BI, Lippman ME. Targeting RAGE signaling in inflammatory disease. Annu Rev Med 2018; 69 (01) 349-364
• 129 Fu Y, Xiang Y, Wang Y. et al. The STAT1/HMGB1/NF-κB pathway in chronic inflammation and kidney injury after cisplatin exposure. Theranostics 2023; 13 (09) 2757-2773
• 130 Qiao X, Li W, Zheng Z. et al. Inhibition of the HMGB1/RAGE axis protects against cisplatin-induced ototoxicity via suppression of inflammation and oxidative stress. Int J Biol Sci 2024; 20 (02) 784-800
• 131 Fan J, He K, Zhang Y, Li R, Yi X, Li S. HMGB1: new biomarker and therapeutic target of autoimmune and autoinflammatory skin diseases. Front Immunol 2025; 16: 1569632
• 132 Wang H, Yu T, An N. et al. Enhancing regulatory T-cell function via inhibition of high mobility group box 1 protein signaling in immune thrombocytopenia. Haematologica 2022; 108 (03) 843-858
• 133 Zhang Y, Bao S, Zeng J. et al. HMGB1 secretion by resveratrol in NSCLC: a pathway to ferroptosis-mediated platelet activation suppression. Cell Signal 2025; 127: 111607